Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus

Endocrine Journal

Volumn 57, Issue 10, 2010, Pages 903-908

  Okada, Kenta ^a,b   Yagyu, Hiroaki ^b   Kotani, Kazuhiko ^b   Miyamoto, Michiaki ^b   Osuga, Jun ichi ^b   Nagasaka, Shoichiro ^b   Ishibashi, Shun ^b  

^a Utsunomiya Social Insurance Hospital   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

C reactive protein; Cholestanol; Cholesterol absorption; LDL cholesterol; Non HDL cholesterol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CAMPESTEROL; CHOLESTANOL; EZETIMIBE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITOSTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID ABSORPTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AZETIDINES; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTANOL; CHOLESTEROL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PHYTOSTEROLS; SITOSTEROLS;

EID: 78649386408     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-055     Document Type: Article

References (26)

1. Sone H, Katagiri A, Ishibashi S, Abe R, Saito Y, Murase T, Yamashita H, Yajima Y, Ito H, Ohashi Y, Akanuma Y, Yamada N; JD Study Group (2002) Effects of lifestyle modifications on patients with type 2 diabetes: the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three yearinterim report. Horm Metab Res 34: 509-515.
2. UK Prospective Diabetes Study (UKPDS) Group (1998). Lancet 352: 837-853.
3. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T (1996) Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes 45: S14-S16.
4. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M (2007) Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of artherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14: 45-50.
5. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (2001) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 285: 2486-2497.
6. Haffner SM (2004) American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 27: S68-S71.
7. Sone H, Mizuno S, Fujii H, Yoshimura Y, Yamasaki Y, Ishibashi S, Katayama S, Saito Y, Ito H, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study. (2005) Is the Diagnosis of Metabolic Syndrome Useful for Predicting Cardiovascular Disease in Asian Diabetic Patients?. Diabetes Care 28: 1463-1471.
8. Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz EJ, Davis HR Jr. (1997) In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 283: 157-163.
9. Van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, Davis HR Jr. (2000) Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 129: 1748-1754.
10. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP; Ezetimibe Study Group. (2003) Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24: 729-741.
11. Bruckert E, Giral P, Tellier P (2003) Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 107: 3124-3128.
12. Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW (2008) The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin 24: 685-694.
13. Seino H, Yamamoto A (2007) Effects of Ezetimibe on the metabolisms of lipid and glucose -Study in the type 2 diabetic patients with hypercholesteremia (in Japanese with an English abstract). J Clin Ther Med 23: 571-588.
14. Derosa G, D'Angelo A, Franzetti IG, Ragonesi PD, Gadaleta G, Scalise F, Ciccarelli L, Piccinni MN, Cicero AF(2009) Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J Clin Pharm Ther 34: 267-276.
15. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
16. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, et al. (1993) Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 223: 53-71.
17. Miettinen TA, Ahrens EH Jr, Grundy SM (1965) Quantitative isolation and gas-liquid chromatographic analysis of total dietary and fecal neutral steroids. J Lipid Res 6: 411-424.
18. Lally S, Tan CY, Owens D, Tomkin GH (2006) Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 49: 1008-1016.
19. Simonen PP, Gylling HK, Miettinen TA (2002) Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care 25: 1511-1115.
20. Gylling H, Miettinen TA (1997) Cholesterol absorption, synthesis, and LDL metabolism in NIDDM. Diabetes Care 20: 90-95.
21. Kalogirou M, Tsimihodimos V, Gazi I, Filippatos T, Saougos V, Tselepis AD, Mikhailidis DP, Elisaf M (2007) Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 23: 1169-1176.
22. Frost PH, Havel RJ (1998) Rationale for use of nonhigh- density lipoprotein cholesterol rather than lowdensity lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 81: B26-B31.
23. Miettinen TA, Tilvis RS, Kesäniemi YA (1989) Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men. Metabolism 38: 136-140.
24. Silbernagel G, Fauler G, Hoffmann MM, Lutjohann D, Winkelmann BR, Boehm BO, Marz W (2010) The associations of cholesterol metabolism and plasma plant sterols with all-cause- and cardiovascular mortality. J Lipid Res 51: 2384-2393.
25. Hoenig MR, Rolfe BE, Campbell JH (2006) Cholestanol: a serum marker to guide LDL cholesterollowering therapy. Atherosclerosis 184: 247-254.
26. Strandberg TE, Tilvis RS, Pitkala KH, Miettinen TA (2006) Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. J Am Coll Cardiol 48: 708-714.